Stockreport

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Vaccinex, Inc.  (VCNX) 
PDF Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 20 [Read more]